secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001493152-25-001782
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma receives NYSE American notice for failure to hold 2024 annual meeting
--------------------------------------------------------------------------------

- On January 6, 2025, Matinas received NYSE American notice for failing to hold 2024 annual meeting, violating Section 704.
- Company plans to hold annual meeting no later than December 31, 2025 to cure deficiency.
- Common stock continues trading on NYSE American with '.BC' indicator during cure period.
- Risks disclosed include sale of MAT 2203 and evaluation of alternatives including winddown or dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225001782/0001493152-25-001782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225001782/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer